Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 2001 Oct;85(10):1174–1178. doi: 10.1136/bjo.85.10.1174

Is activated factor VII associated with retinal vein occlusion?

S Kadayifcilar 1, D Ozatli 1, O Ozcebe 1, E Sener 1
PMCID: PMC1723720  PMID: 11567960

Abstract

AIM—To determine whether a newly identified thrombophilia factor, activated factor VII (FVIIa), is associated with retinal vein occlusion (RVO).
METHODS—54 consecutive cases with RVO seen between March and September 1999 were included in the study. 22 cases had central retinal vein occlusion (CRVO) and 32 had branch retinal vein occlusion (BRVO). Ophthalmoscopic examination with detailed medical history was followed by blood analyses for liver and renal functions, cholesterol, triglycerides, complete blood count, and coagulation factors including protein C activity, free protein S, antithrombin III, fibrinogen, and factor VIIa (FVIIa). Data were compared with those of the control group, composed of 19 cases under ophthalmological follow up for refractive errors, presbyopia, or senile cataract.
RESULTS—Hypertension was highly prevalent in cases with BRVO. Complete blood count, and liver and kidney function tests were within normal limits in the study group. Two cases had low protein C activity, and one had low free protein S. FVIIa levels were significantly higher in the RVO group than in the control group (p=0.0004). There was no significant difference in FVIIa levels between the CRVO and BRVO groups (p=0.51).
CONCLUSION—No haematological parameter except FVIIa differed significantly from that of the control group. Elevation of FVIIa level may play a part in the pathophysiology of both CRVO and BRVO.



Full Text

The Full Text of this article is available as a PDF (141.8 KB).

Figure 1  .

Figure 1  

Open in a new tab

Activated factor VII levels in central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), and control group. The black lines in the box plot diagram show the median values of the groups (◯ = outlier cases, * = extreme cases).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bandello F., Viganò D'Angelo S., Parlavecchia M., Tavola A., Della Valle P., Brancato R., D'Angelo A. Hypercoagulability and high lipoprotein(a) levels in patients with central retinal vein occlusion. Thromb Haemost. 1994 Jul;72(1):39–43. [PubMed] [Google Scholar]
  2. Bauer K. A. Activation of the factor VII-tissue factor pathway. Thromb Haemost. 1997 Jul;78(1):108–111. [PubMed] [Google Scholar]
  3. Bhagat N., Goldberg M. F., Gascon P., Bell W., Haberman J., Zarbin M. A. Central retinal vein occlusion: review of management. Eur J Ophthalmol. 1999 Jul-Sep;9(3):165–180. doi: 10.1177/112067219900900304. [DOI] [PubMed] [Google Scholar]
  4. Dodson P. M., Galton D. J., Hamilton A. M., Blach R. K. Retinal vein occlusion and the prevalence of lipoprotein abnormalities. Br J Ophthalmol. 1982 Mar;66(3):161–164. doi: 10.1136/bjo.66.3.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Heinrich J., Balleisen L., Schulte H., Assmann G., van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb. 1994 Jan;14(1):54–59. doi: 10.1161/01.atv.14.1.54. [DOI] [PubMed] [Google Scholar]
  6. Kapiotis S., Jilma B., Pernerstorfer T., Stohlawetz P., Eichler H. G., Speiser W. Plasma levels of activated factor VII decrease during the menstrual cycle. Thromb Haemost. 1998 Oct;80(4):588–591. [PubMed] [Google Scholar]
  7. Kario K., Matsuo T., Tai S., Sakamoto S., Yamada T., Miki T., Matsuo M. Congenital protein C deficiency and myocardial infarction:concomitant factor VII hyperactivity may play a role in the onset of arterial thrombosis. Thromb Res. 1992 Jul 1;67(1):95–103. doi: 10.1016/0049-3848(92)90261-8. [DOI] [PubMed] [Google Scholar]
  8. Kario K., Miyata T., Sakata T., Matsuo T., Kato H. Fluorogenic assay of activated factor VII. Plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese. Arterioscler Thromb. 1994 Feb;14(2):265–274. doi: 10.1161/01.atv.14.2.265. [DOI] [PubMed] [Google Scholar]
  9. Kelleher C. C. Plasma fibrinogen and factor VII as risk factors for cardiovascular disease. Eur J Epidemiol. 1992 May;8 (Suppl 1):79–82. doi: 10.1007/BF00145355. [DOI] [PubMed] [Google Scholar]
  10. Larsson J., Olafsdottir E., Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol. 1996 Mar;80(3):200–202. doi: 10.1136/bjo.80.3.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Larsson J., Sellman A., Bauer B. Activated protein C resistance in patients with central retinal vein occlusion. Br J Ophthalmol. 1997 Oct;81(10):832–834. doi: 10.1136/bjo.81.10.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lip G. Y., Blann A. D. Does hypertension confer a prothrombotic state? Virchow's triad revisited. Circulation. 2000 Jan 25;101(3):218–220. doi: 10.1161/01.cir.101.3.218. [DOI] [PubMed] [Google Scholar]
  13. Lip P. L., Blann A. D., Jones A. F., Lip G. Y. Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye (Lond) 1998;12(Pt 2):245–251. doi: 10.1038/eye.1998.58. [DOI] [PubMed] [Google Scholar]
  14. Meade T. W., Mellows S., Brozovic M., Miller G. J., Chakrabarti R. R., North W. R., Haines A. P., Stirling Y., Imeson J. D., Thompson S. G. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986 Sep 6;2(8506):533–537. doi: 10.1016/s0140-6736(86)90111-x. [DOI] [PubMed] [Google Scholar]
  15. Miller G. J., Wilkes H. C., Meade T. W., Bauer K. A., Barzegar S., Rosenberg R. D. Haemostatic changes that constitute the hypercoagulable state. Lancet. 1991 Oct 26;338(8774):1079–1079. doi: 10.1016/0140-6736(91)91936-o. [DOI] [PubMed] [Google Scholar]
  16. Morrissey J. H., Macik B. G., Neuenschwander P. F., Comp P. C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 1993 Feb 1;81(3):734–744. [PubMed] [Google Scholar]
  17. Petri M., Nelson L., Weimer F., Anderson D., Darlington T., Corash L. The automated modified Russell viper venom time test for the lupus anticoagulant. J Rheumatol. 1991 Dec;18(12):1823–1825. [PubMed] [Google Scholar]
  18. Vine A. K., Samama M. M. The role of abnormalities in the anticoagulant and fibrinolytic systems in retinal vascular occlusions. Surv Ophthalmol. 1993 Jan-Feb;37(4):283–292. doi: 10.1016/0039-6257(93)90011-u. [DOI] [PubMed] [Google Scholar]
  19. Williamson T. H., Rumley A., Lowe G. D. Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol. 1996 Mar;80(3):203–208. doi: 10.1136/bjo.80.3.203. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES